Additionally, a longitudinal analysis of serum GFAP In COVID-19 patients with varying severity revealed a normalization of GFAP expression 6 months after the initial serological analysis, despite the persistence of neurological symptoms in 50% of the cohort (i.e., fatigue, brain fog, and impaired cognition) [85]. Here, GFAP is linked to COVID-19.